Signature of survival: a <sup>18</sup>F-FDG PET based whole-liver radiomic analysis predicts survival after <sup>90</sup>Y-TARE for hepatocellular carcinoma.
The aim of this article was to evaluate the prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on preoperative F-FDG PET/CT for predicting intrahepatic recurrence-free survival (IHRFS), extrahepatic metastasis-free survival (EHMFS), and overall survival (OS) in patients with very early/early hepatocellular carcinoma (HCC).
ADC values and <sup>18</sup>F-FDG uptake measured using DW MRI and <sup>18</sup>F-FDG PET serve as potential biomarkers for early assessment of HCC tumor responses to radiation therapy.
The images showed abnormal FDG uptake in the left lobe and hilum of the liver, which was confirmed as hepatocellular carcinoma and hepatic portal bile duct tumor thrombus, respectively, by the pathology.
Similarly, pooled specificity was comparable with CT (93%) or without 95% (P = .481).F-FDG PET, with or without CT, shows relatively low sensitivity but high specificity for diagnosing extrahepatic metastases or local residual/recurrent HCC.
18F-FDG PET/CT predicts microvascular invasion and early recurrence after liver resection for hepatocellular carcinoma: A prospective observational study.
Pretreatment tumour metabolic activity assessed by <sup>18</sup>F-FDG PET is an independent prognostic factor for survival in patients with BCLC-C stage HCC receiving sorafenib monotherapy, although it may not predict tumour response to the treatment.
We describe a case of telbivudine-induced myopathy visualized on FDG PET/CT in a 75-year-old man with history of chronic HBV infection and hepatocellular carcinoma.
A 53-year-old man with tentative diagnosis of likely hepatocellular carcinoma underwent FDG PET/CT, which showed intense activity in both right lobe and caudate lobe of the liver.
Despite the observed reasonable diagnostic performance of FDG-PET SUV<sub>max</sub> for HCC detection and several significant correlations between FDG-PET SUV and DCE-MRI parameters, FDG-PET did not provide clear additional value for HCC characterization compared to mpMRI in this pilot study.
This study aimed to examine tumoral and background standardized uptake value (SUV) alterations in dual-phase F-FDG PET/computed tomography (CT) imaging.Fifty-two HCC cases underwent dual-time-point F-FDG PET/CT examination where early and delayed images were obtained.
The sensitivity, specificity and accuracy values of contrast-enhanced <sup>18</sup>F-FDG PET/CT examination in the detection of HCC recurrence were 92.8%, 94.1% and 93%, respectively.
The in vitro cellular uptake, in vivo micro-PET/CT imaging and biodistribution studies of 68Ga-NGR and 18F-FDG were quantitatively compared in SMMC-7721-based well‑differentiated HCC xenografts.
The comparison of the imaging results of the two methods showed that <sup>99m</sup>Tc-3PRGD<sub>2</sub> integrin receptor imaging was more sensitive than <sup>18</sup>F-FDG metabolic imaging for the detection of early stage HCC, meanwhile the tumour uptake of <sup>99m</sup>Tc-3PRGD<sub>2</sub> was consistently higher than that of <sup>18</sup>F-FDG.